

11. (Twice Amended) The preparation of 1, wherein at least one amphiphilic lipid component is selected from the group consisting of a diacyl or a dialkyl glycerophosphoethanolamino azo polyoxyethylene derivative, a didecanoyl phosphatidyl choline, a diacyl phosphooligomaltobionamide, a glyceride, a glycerophospholipid, a isoprenoid lipid, a sphingolipid, a steroid, a sterol, a sulfur-containing or a hydrocarbon-containing lipid, a half protonated liquid fatty acid, a phosphatidyl choline, a phosphatidyl ethanolamine, a phosphatidyl glycerol, a phosphatidyl inositol, a phosphatid acid, a phosphatidyl serine, a sphingomyelin or a sphingophospholipid, glycosphingolipid, a cerebroside, a ceramide polyhexoside, a sulfatide, a sphingoplasmalogen a ganglioside, a glycolipid, a synthetic lipid, a dioleoyl, a dilinoyl, a dilinolenyl, a dilinoloyl, a dilinolinoyl or a diarachinoyl, a dilauroyl, a dimyristoyl, a dilalmitoyl, a distearoyl phospholipid, a corresponding dialkyl, a sphingosin derivative, and a glycolipid.

12. (Twice Amended) The preparation of claim 1, wherein the less soluble amphiphilic lipid component is selected from the group consisting of a myristoleoyl, a palmitoleoyl, a petroselinyl, a petroselaidyl, a oleoyl, elaidyl, a cis- or trans- vaccenoyl, a linoyl, a linolenyl, a linolaidyl, a octadecatetraenoyl, a gondoyl, a eicosaenoyl, a eicosadienoyl, a eicosatrienoyl, a arachidoyl, a cis- or trans-docosaenoyl, a docosadienoyl, a docosatrienoyl, a docosatetraenoyl, a caproyl, a lauroyl, a tridecanoyl, a myristoyl, a pentadecanoyl, a palmitoyl, a heptadecanoyl, a stearoyl or a nonadecanoyl, a glycerophospholipid, a glycolipid, an acyl lipid, and an alkyl lipid.

15. (Twice Amended) The preparation of claim 1, wherein the active ingredient is selected from the group consisting of an adrenocorticostatic agent, a β -adrenolytic agent, an androgen or antiandrogen, an anti-parasitic, an anabolic, an anesthetic or an analgesic, an analeptic, an anti-allergic, an anti-arrhythmic, an anti-arteriosclerosis, an anti-asthmatic, a bronchospasmolytic agent, an antibiotic, an anti-depressive, an anti-psychotic agent, an anti-diabetic agent, an antidote, an anti-emetic, an anti-epileptic, an

anti-fibrinolytic, an anti-convulsive, an anti-cholinergic agent, an enzyme, a coenzyme, a corresponding coenzyme inhibitor, an antihistamine, an antihypertensive drug, a biological activity inhibitor, an antihypotensive agent, an anticoagulant, an anti-mycotic, an antimyasthenic agent, an active ingredient against Parkinson's or Alzheimer's disease, an anti-phlogistic, a anti-pyretic or an anti-rheumatic agent, an antiseptic, a respiratory analeptic, a stimulating agent, a broncholytic, a cardiotonic, a chemotherapeutic agent, a coronary dilator, a cytostatic agent, a diuretic, a ganglion blocker, a glucocorticoid, a therapeutic agent for influenza, a hemostatic agent, a hyptonic agent, an immunoglobulin, a fragment or a different immunological, a receptor substance, a bioactive carbohydrate, a bioactive carbohydrate derivative, a contraceptive, a migraine agent, a mineral corticoid, a morphine antagonist, a muscle relaxant, a narcotic, a neural therapeutic agent, a CNS therapeutic agent, a nucleotide, a polynucleotide, a neuroleptic agent, a neuron transmitter, a neuron transmitter antagonist, a peptide, a peptide derivative, an ophthalmic agent, a para-sympathicomimetic or para-sympathicolytic agent, a protein, a protein derivative, a psoriasis/neurodermatitis agent, a mydriatic agent, a mood elevator, a rhinological agent, a sleeping draft, a sleeping draft antagonist, a sedative, a spasmolytic, a tuberculosis agent, a urological agent, a vasoconstrictor, a vasodilator, a virostatic agent, a wound-healing agent, diclofenac and ibuprofen.

REMARKS

Claims 1, 3-13 and 15-52 are pending in the application. In this response, claims 5-6, 11-12 and 15 have been amended. Support for these amendments is found throughout the specification and claims as filed, and it is respectfully submitted that no new matter has been added by virtue of this amendment.

Rejection Under 35 U.S.C. §112, Second Paragraph

In the Office Action, claims 1, 3-13 and 15-52 were rejected as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In particular, the Examiner stated that "amended claim 5 does not appear to be